Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine the effectiveness of enzastaurin in the treatment of patients with metastatic breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Taxane

Criteria

Inclusion Criteria:

• Clinical diagnosis of metastatic breast cancer or recurrent breast cancer where surgery can not be done for curative intent

• Have received prior therapy with an anthracycline (class of drugs) and a taxane (class of drugs).

• Tumors must not be positive for HER2, but if positive, the treatment plan should not include further treatment with the drug Herceptin.

• Disease that can be definitely measured on Cat Scans or other radiological tests.

• May have received high dose chemotherapy for autologous stem cell support greater than or equal to 6 months of starting this study.

Exclusion Criteria:

• More than 2 chemotherapy regimens for metastatic or locally recurrent disease.

• Have brain cancer from breast cancer

• Pregnant or breastfeeding

• Have an inability to swallow tablets

• Within 6 months have had a serious heart condition